ERBB2 and non-small cell lung carcinoma: In contrast to the poor outcome in non‐small‐cell lung cancer (NSCLC) with ERBB2 alterations,26ERBB2‐mutated BTC patients showed improved PFS compared with those of wild‐type ERBB2 (mPFS, NR vs 3.0 months, HR = 0.15; 95% CI, 0.02‐1.19; P = .039; 6‐month PFS rate = 80.0% vs 16.7%; Figures 2B and 6B).